Add BrightSurf on Google Email

A unique clinical trial leads to a dramatic decrease in early deaths from the rare and aggressive—yet highly curable—acute promyelocytic leukemia (APL)

A unique clinical trial has achieved a remarkable 97% induction survival rate in patients with acute promyelocytic leukemia (APL) by providing a simplified treatment regimen and 24/7 support from APL experts. This collaborative care model, known as EA9131, significantly reduced early deaths and improved overall survival rates.

Extending chemo slashes risk of aggressive childhood leukemia coming back

A new treatment protocol has been shown to significantly reduce the risk of aggressive childhood leukemia returning after chemotherapy. The ALL-11 protocol, which includes an extra year of maintenance chemotherapy for children with specific genetic mutations, has improved five-year survival rates and quality of life for these patients....

SourcePrincess Máxima Center for Pediatric Oncology·TypeRandomized controlled/clinical trial·DateDec 10, 2022

Albert Einstein College of Medicine receives $6.6M in NIH grants to lead New York consortium for kidney, urological, and hematological research and training

The National Institutes of Health has awarded Albert Einstein College of Medicine a five-year, $6.6 million grant to train young scientists in kidney, urology, and hematology research. The New York Consortium for Interdisciplinary Training in Kidney, Urological, and Hematological Research will bring together experts from four medical s...

CAR T-Cell therapy outcomes similar across different socioeconomic levels among pediatric patients with ALL

A new study finds no significant difference in overall survival or complete remission rates between children and young adults with different levels of poverty exposure, regardless of their neighborhood opportunity. CAR T-cell therapy is equally effective for those from disadvantaged households as it is for those from more socioeconomic...

Being lonely and unhappy accelerates aging more than smoking

A recent study published in Aging-US found that feeling lonely, unhappy, or hopeless increases one's biological age more than smoking. The research used digital models of aging to analyze the effects of various factors on aging rates, revealing a significant correlation between mental health and accelerated aging.

SourceDeep Longevity Ltd·JournalAging-US·TypeData/statistical analysis·DateSep 27, 2022

Diversity is everyone’s responsibility: Researchers outline a path to representation in cancer clinical trials

Researchers outline a five-step approach to increase racial representation in cancer clinical trials through DRIVE: Diversity officer, Ranking of clinical studies, Individual diversity plan, Verification, and Training. This can lead to more inclusive and individualized treatment for diverse patient populations.

SourceAmerican Society of Hematology·JournalBlood Advances·DateAug 25, 2022

There’s a better way to detect high-risk medications in older adults with cancer according to new study in JNCCN

A new scale called the Geriatric Oncology-Potentially Inappropriate Medications (GO-PIMs) Scale was found to be more effective at predicting frailty than conventional methods. The scale identifies high-risk medications linked to falls and fatigue, allowing oncology teams to deprescribe them and improve patients' overall health.

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateAug 10, 2022

Chemotherapy drugs from “rogue” online pharmacies could endanger leukemia patients, suggests research in JNCCN

A study found that a majority of online pharmacies selling imatinib, a chronic myeloid leukemia therapy, are uncertified and operate unsafely. Patients may face risks of nonadherence, treatment failures, and adverse events if they use these pharmacies.

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·TypeSystematic review·DateJul 28, 2022

Young Black patients with AML face significantly worse outcomes than white patients of the same age

A new study published in Blood Advances highlights significant inequities in diagnosis, treatment, and care between Black and white patients with acute myeloid leukemia (AML). Young adult Black patients were five times more likely to die within 30 days of beginning treatment compared to comparable white patients. The study also found c...

SourceAmerican Society of Hematology·JournalBlood Advances·DateJul 5, 2022

New research to help address blood shortages in Ireland

A study by RCSI University of Medicine and Health Sciences has identified barriers and motivators to blood donation for people from ethnic minority groups in Ireland. Factors that motivate people from minority ethnic backgrounds to give blood include religious reasons and a desire to help others in their own communities.

SourceRCSI·DateJun 17, 2022

The cost of living with sickle cell disease

A new study reveals that individuals with sickle cell disease spend approximately $1.7 million on lifetime medical expenses, highlighting the significant economic burden of living with this disease. The study found that out-of-pocket costs for those with private insurance plans can be as high as 5-10% of their annual income.

SourceAmerican Society of Hematology·JournalBlood Advances·DateMay 16, 2022

Study shines light on fertility education gaps among adolescent and young adult men with sickle cell disease

A new study found that many adolescent and young adult men with sickle cell disease are unaware of potential fertility issues associated with the disorder. The research suggests a need for accessible fertility education and testing options to address this knowledge gap, particularly in how SCD and treatments may affect fertility.

SourceAmerican Society of Hematology·JournalBlood Advances·DateApr 20, 2022

MSK Chief of the Lymphoma Service Gilles Salles Presents Promising New Treatment for Patients with Diffuse Large B-Cell Lymphoma

Researchers at Memorial Sloan Kettering Cancer Center found that pola-R-CHP reduces the risk of DLBCL disease progression, relapse, or death by 27 percent. The treatment, combining Polatuzumab vedotin with Rituximab and other chemotherapy agents, shows improved progression-free survival rates compared to current standard R-CHOP therapy.

SourceMemorial Sloan Kettering Cancer Center·JournalNew England Journal of Medicine·DateDec 14, 2021

Organizations collaborate to develop international von Willebrand Disease guidelines

The American Society of Hematology, International Society on Thrombosis and Haemostasis, National Hemophilia Foundation, and World Federation of Hemophilia have developed joint clinical practice guidelines for von Willebrand Disease (VWD). The guidelines provide recommendations for diagnosis and management, including the use of injecta...

SourceAmerican Society of Hematology·JournalBlood Advances·DateJan 12, 2021

Identified the genetic landscape of myelodysplastic/myeloproliferative neoplasms

A study published in the Journal Blood reveals the molecular landscape of myelodysplastic/myeloproliferative neoplasms (MDS/MPN), a group of rare malignancies with overlapping features. The researchers identified genotype-phenotype associations and potential diagnostic molecular markers that can improve diagnosis and risk stratificatio...

The Lancet Haematology: First global estimates suggest around 100 million more blood units are needed in countries with low supplies each year

The global demand for blood transfusions exceeds the available supply by 30 million units annually, with the largest shortages found in lower-income countries. The estimated shortfall varies sharply between countries, with some requiring up to 75 times more blood than their supply can provide.

SourceThe Lancet·JournalThe Lancet Haematology·DateOct 17, 2019